Exosome Diagnostics Announces Roger Henriksson, M.D., Ph.D. is Joining its Scientific Advisory Board

NEW YORK, Oct. 6 /PRNewswire/ -- Exosome Diagnostics, Inc. today announced that Roger Henriksson, M.D., Ph.D. has joined the company's scientific advisory board.

Dr. Henriksson is head of the Dept of Radiation Sciences, and chief physician of the Section of Neuro-Oncology, Lung Carcinoma and Malignant Melanoma at University Hospital, Umea, Sweden. In addition, Dr. Henriksson serves as a senior medical advisor to AstraZenica, chairman of the North Sweden Cancer Society, chairman of the National Group for Treatment of CNS Tumors and as a board member of the National Group for Treatment of Lung Cancer in Sweden. Dr. Henriksson has served as director of clinical studies, Department of Oncology, and head of the Experimental Research Unit in the Department of Oncology at University Hospital, Umea. He is former member of the scientific advisory board for the Swedish Cancer Society. Dr. Henriksson has authored 274 publications in peer review journals, including publications in all phases of drug development.

"Dr. Henriksson's addition to our scientific advisory board will add another experienced voice to our group of distinguished medical leaders," said James McCullough, chairman and chief executive officer. "His counsel will be invaluable as we expand our clinical trials to examine both the level and mutational profile of nucleic acids found in blood exosomes for our cancer diagnostics program."

About Exosome Diagnostics

Exosome Diagnostics is a developer of proprietary genetics-based diagnostic tests with applications in oncology and metabolic disease. The company's core technology is based on the discovery that circulating nanovesicles called exosomes contain unique genetic markers that can be reliably harvested from blood and used diagnostically for cancers and metabolic diseases. Exosome Diagnostics' lead program is a blood-based diagnostic test for the management of brain tumor patients. For more information, visit www.exosomedx.com.

CONTACT: Robert Flamm, Ph.D., robert.flamm@russopartnersllc.com, or David
Schull, david.schull@russopartnersllc.com, both of Russo Partners, LLC,
+1-212-845-4226

Web site: http://www.exosomedx.com/

Back to news